A C C E P T E D M A N U S C R I P T
7 experiments by the Ministry of Health, Labor and Welfare, and approved by the Animal Care and Use Committee of Tokyo Metropolitan Institute of Gerontrogy. Female A/J mice (Japan SLC) were used after 4 months of age. On day 0, mice were anesthetized with a mixture of medetomidine, midazolam, and butophanol, followed by subcutaneous injection in the hind footpads with 10 μg of LRP4 emulsified with complete Freund's adjuvant (Sigma-Aldrich). All mice were boosted with 10 μg of recombinant LRP4 emulsified with incomplete Freund's adjuvant (Sigma-Aldrich) on day 14. Mice that did not lose body weight (BW) after the second injection received a third injection of the same dose of LRP4 emulsified with incomplete adjuvant on day 35. Control mice were injected with equal volumes of PBS emulsified with adjuvant in the same manner on days 0, 14, and 35.
Thirty-three mice (11 control mice, 22 LRP4-injected mice) were used in this study. Mice were weighed and inspected for general health daily. When LRP4-immunized mice exhibited gait disturbance and lost more than 20% of their BW (based on the value at the time of the second or third injection), inspection was terminated and mice were analyzed for EAMG. Blood samples were collected from the tail vein (for detection of anti-LRP4 antibodies) or the heart (for AChR clustering and MuSK phosphorylation assays) under anesthesia at the end of the experimental period. Six mice immunized with LRP4 were excluded from the analysis because they exhibited a significant increase in BW after the third immunization, and their anti-LRP4 Ab titers were significantly lower than those of mice exhibiting myasthenic weakness.
Muscle strength measurements
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A C C E P T E D M A N U S C R I P T 8 Muscle strength was evaluated by an inverted screen test, performed with a wire cage lid apparatus (O'Hara & Co., Ltd., Tokyo, Japan). The mouse was placed on a wire mesh, which was then smoothly inverted and held above a soft surface. The time that the mouse hung from the wire lid before falling was recorded. Mice were scored according to this time, as follows (Cossins et al., 2004) : 1, 0-10 s; 2, 11-25 s; 3, 26-60 s; 4, 61-100 s; 5, 101-119 s; and 6, 120+ s.
ELISA assay to detect anti-LRP4 antibodies
Wells of an ELISA plate were coated with recombinant human LRP4 protein (150 ng/well) diluted in Tris-buffered saline (TBS). After washing with 0.1% Tween-20 in TBS (TBST), plates were blocked with 4% BlockAce (Dainippon Pharmaceutical, Osaka, Japan) and incubated for 2 h with mouse serum (diluted 1:1000). Plates were washed, incubated for 1 h with horseradish peroxidase-conjugated sheep anti-mouse IgG antibodies (diluted 1:3000; GE Healthcare), washed again, and reacted with o-phenylenediamine dihydrochloride peroxidase substrate (Sigma-Aldrich). The colorimetric reaction was stopped by the addition of 2 N HCl.
Absorbance values at 490 nm were determined. Subclasses of anti-LRP4 antibodies were determined by using a Mouse Typer Sub-Isotyping Kit (Bio-Rad Laboratories, Hercules, CA), according to the manufacturer's instructions. For isotyping analysis, serum from LRP4-immunized mice was diluted 1:3000.
Cell-based assay to detect anti-LRP4 antibodies
Full-length human LRP4 cDNA fused to mCherry cDNA at its C terminus was inserted
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A C C E P T E D M A N U S C R I P T 9 into the pMX plasmid. Retroviral packaging Plat-E cells, cultured in 10% FCS/DMEM, were transfected with the LRP4-mCherry expression plasmid by using FuGENE6 (Promega Corp., Madison, WI). Two days after transfection, indirect immunofluorescence staining of the transfected cells was performed. Cells were incubated with mouse serum (diluted 1:50) for 1 h at 37 °C, washed with serum-free DMEM, and fixed with 2% paraformaldehyde (PFA) in PBS for 15 min. Cells were washed with PBS, blocked with 1% BSA in PBS for 30 min, and incubated with Alexa Fluor 488-labeled goat anti-mouse IgG Abs (1 μg/ml; Life Technologies) for 1 h.
After washing, the cells were mounted with Fluoromount/Plus (Diagnostic Biosystems, Pleasanton, CA). A Leica DMI6000 microscope (Leica Microsystems, Buffalo Grove, IL) was used to obtain fluorescence images.
EMG
Changes in compound muscle action potential (CMAP) were determined as described previously (Mori et al., 2012a) . Trains of 10 impulses were applied at 3, 10, 20, and 40 Hz with a 10-30 s pause between trains. Decrement was calculated as the percent amplitude change between the first CMAP and the smallest CMAP evoked by a train of 10 impulses.
In-vitro electrophysiology
Membrane potentials (MPs) and miniature endplate potentials (MEPPs) were recorded by using a specimen composed of the left phrenic nerve and hemidiaphragm muscle, as described previously (Mori et al., 2012b) . To measure evoked endplate potentials (EPPs), 1 μM A C C E P T E D M A N U S C R I P T 10 μ-conotoxin GIIIB (Peptide Institute, Osaka, Japan) was applied to suppress muscle contraction.
The phrenic nerve was stimulated by a suction electrode with supramaximal voltage at 0.7 Hz.
Amplitudes of EPPs and MEPPs were standardized to MP of -75 mV. Quantal content was calculated as described previously (Mori et al., 2012a) .
Preparation of anti-bassoon antibodies
We used a synthetic DNA fragment corresponding to residues 738-1035 of the deduced primary sequence of rat bassoon, which is an identical region to the immunogen used to generate a commercially available monoclonal Ab (clone: SAP7F407). The fragment was inserted into the pCold II expression vector (Takara Bio Inc., Otsu, Japan). Recombinant protein with an N-terminal His-tag was expressed in E. coli BL21 cells and purified from bacterial lysate by Ni-Sepharose beads. Antiserum against bassoon was prepared by injecting Wistar rats thrice with purified recombinant bassoon protein.
Immunofluorescence staining of NMJs
Mice were fixed by transcardiac perfusion with 2% PFA in PBS. Soleus muscles were Whole-mount staining of NMJs in soleus muscle was performed as described previously (Mori et al., 2012a) . Confocal images were acquired on a Leica TCS SP8 confocal laser-scanning unit with a 63× oil objective (for longitudinal sections) or 63× glycerin objective (for whole mounts) on a Leica DMI6000 microscope. Staining intensity and area of AChR clusters (in whole mounts) and areas of bassoon and synaptophysin staining (in longitudinal sections) were quantified from the maximum projection of confocal images with ImageJ software (NIH, Bethesda, MD). The threshold for each image was defined with the ImageJ Auto Threshold program. The same algorithm was used for all images, to ensure that staining signal quantification was as objective as possible.
AChR clustering assay
C2C12 myotubes were prepared in 24-well plates, as described previously (Mori et al., 2012a) . Myotubes were treated with mouse serum (diluted 1:50) in the presence or absence of 1 nM agrin, prepared as described previously (Phillips et al., 2014) . AChR clusters were visualized with 40 nM Alexa Fluor 488-conjugated BTx (Life Technologies) in fusion medium for 1 h before fixation. Fluorescence images of myotubes were acquired by using a 20× objective on a Leica DMI6000 microscope. Numbers of AChR clusters in eight randomly selected fields were ACCEPTED MANUSCRIPT A C C E P T E D M A N U S C R I P T 12 counted by using Imaris software (Bitplane, Zurich, Switzerland).
Overexpression of Dok-7 in C2C12 myotubes
Full-length mouse Dok-7 cDNA with an N-terminal mCherry tag was inserted into the pMX expression vector. Plat-E cells were transfected with the pMX-mCherry-Dok-7 expression vector by using FuGENE6 (Promega Corp.). The next day, growth medium was changed, and CM containing retroviral particles was harvested after an additional 24 h. C2C12 myoblasts seeded in 24-well plates were infected with retroviruses until the cells reached confluency and differentiated into myotubes, to investigate the effect of serum on Dok-7-induced AChR clustering.
MuSK phosphorylation assay
Myotubes treated with mouse serum (diluted 1:50) in the presence or absence of 1 nM agrin were lysed in TBS containing 0.5% NP-40, 1 mM EDTA, protease inhibitor cocktail (Roche, Basel, Switzerland), and 2 mM sodium orthovanadate. Clarified cell lysates were incubated with anti-MuSK Abs followed by Protein G Sepharose beads (GE Healthcare). Beads were washed extensively with lysis buffer and solubilized in SDS-PAGE buffer. 
Statistical analyses
All statistical analyses were performed by using KaleidaGraph software (Synergy Software, Reading, PA). Significant differences between control and LRP4-immunized mice were analyzed by unpaired t-test or Mann-Whitney U test. Analysis of variance and Bonferroni's multiple comparison test were used to assess the results of AChR clustering and MuSK phosphorylation assays. P values < 0.05 were considered statistically significant.
Results
Preparation of recombinant LRP4 protein
Our initial experiments focused on generating the human LRP4 ectodomain as a secreted recombinant protein with a C-terminal Myc-His tag (Fig. 1A) . However, we found that transfection of the Expi293F cell line with the LRP4 ectodomain expression vector alone resulted in low levels of LRP4 secretion into the cell culture medium. RAP serves as a molecular chaperone for members of the LDLR family by facilitating receptor folding and trafficking within the early secretory pathway (Bu et al., 1995; Bu and Rennke, 1996) . MESD has also been identified as a novel molecular chaperone that regulates the folding of LDLR family members,
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A C C E P T E D M A N U S C R I P T 14 including LRP5/LRP6 (Hsieh et al., 2003) . Accordingly, we cotransfected Expi293F cells with RAP, MESD, and LRP4 expression vectors to promote secretion of recombinant LRP4 protein into the culture media. Immunoblot analysis of the CM showed a marked increase in LRP4 secretion when cells were cotransfected with all three expression vectors compared to when they were transfected with the LRP4 expression vector alone (Fig. 1B) . Therefore, we routinely cotransfected cells with all three expression vectors and purified the recombinant LRP4 protein from the CM (Fig. 1C) .
LRP4 immunization causes muscle weakness with BW loss in mice
We injected female A/J mice with 10 μg of purified LRP4 protein on days 0, 14, and 35 of the experiment. Fifteen of the 22 LRP4-immunized mice manifested severe muscle weakness with tremors, similarly to MuSK-immunized mice. Myasthenic weakness and significant BW loss were evident within 3 weeks of the second or third immunization. These mice were eventually unable to raise their heads or to move around freely ( Figs. 2A, B ). An inverted screen test revealed that a significant decrease in muscle strength preceded weight loss in LRP4-immunized mice (Fig. 2C) . In contrast, all of the control mice remained healthy, even after the third injection with PBS emulsified in adjuvant.
We used A/J mice to generate the LRP4-induced EAMG model via active immunization.
A/J mice cannot generate the membrane attack complex, which functions as the cytolytic end product of the complement cascade, due to mutations in the complement component gene (C5) (Wetsel et al., 1990) . Moreover, these mice are resistant to the EAMG induced by AChR
immunization (Berman and Patrick, 1980) . Our LRP4-immunized, complement-deficient mice exhibited pronounced MG-like symptoms at a higher incidence than that observed in previous studies. This result shows that complement activation is dispensable for onset of LRP4-mediated EAMG (LRP4-EAMG) in mice (Shen et al., 2013) .
Using an ELISA assay, we found that anti-LRP4 IgG antibodies were detectable in sera from all LRP4-immunized mice exhibiting MG symptoms. Similar to preimmune sera, sera from control mice had no detectable anti-LRP4 antibodies (Fig. 2D) . Isotyping analysis revealed that anti-LRP4 antibodies consisted of three subclasses: IgG1, IgG2a, and IgG2b. IgG3 was barely detected, although it was difficult to compare the quantity of each IgG subclass quantitatively (Fig. 2E) . Next, we used a cell-based assay to examine whether anti-LRP4 antibodies recognize the native form of LRP4. Nonpermeabilized Plat-E cells expressing full-length LRP4 fused to the mCherry fluorescent protein were decorated with sera from LRP4-immunized mice but not with sera from control or MuSK-immunized mice. This observation demonstrates that the anti-LRP4 antibodies were capable of binding the native form of the LRP4 ectodomain (Fig. 2F) .
LRP4 immunization causes impairment of neuromuscular transmission
To assess the capacity for neuromuscular transmission in NMJs, we performed EMG experiments with repetitive nerve stimulation at various frequencies in the gastrocnemius muscles. LRP4-immunized mice showed significant CMAP decrements, whereas control mice did not exhibit any CMAP decrements (Figs. 3A, B) . Although a previous report did not observe significant CMAP decrements with stimulation of less than 20 Hz (Shen et al., 2013) 
studies, CMAP decrements clearly become significant from 3-Hz stimulation (mean: 22.6% ± 3.7%) and maxed out at frequencies above 10 Hz (Figs. 3A-C) . As CMAP showed a decrement of more than 10% during a train of 5 to 10 nerve stimuli at 2 to 5 Hz, the transmission failure was localized at either the post-or pre-synaptic region in NMJs. In mouse models of AChR-MG and MuSK-MG, CMAP decrements are generally observed upon 3-Hz nerve stimulation (Kusner et al., 2015; Phillips et al., 2014) and become more prominent at higher stimulation frequencies (Plomp et al., 2015) . These results demonstrate that LRP4-immunized mice with myasthenia exhibited the characteristic CMAP decrement that has been observed in other MG model mice and in patients.
Next, we analyzed MEPPs and EPPs of LRP4-immunized mice via intracellular
recordings from muscle fibers of excised hemidiaphragms. No significant difference was observed in resting MP between control mice (-73.0 ± 2.17 mV) and LRP4-immunized mice (-68.6 ± 4.29 mV). In LRP4-immunized mice, both MEPP and EPP amplitudes (MEPP, 0.60 ± 0.049 mV; EPP, 14.0 ± 0.65 mV) were significantly decreased compared to controls (MEPP, 1.12 ± 0.046 mV; EPP, 27.4 ± 1.69 mV) (Figs. 3D-G) . In addition, the mean quantal content (steady-state number of quanta released by a single 0.7-Hz nerve impulse) of LRP4-immunized diaphragms fell to 76.4% of the control value (36.2 ± 2.56 vs. 47.3 ± 3.00) (Fig. 3H) . Our results of the ex-vivo EPP recordings corresponded to those of a previous report of LRP4 model mice (Shen et al., 2013) . Both attenuated postsynaptic sensitivity and defective transmitter release could contribute to decreased EPP amplitude, leading to decrements in CMAP amplitude.
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LRP4 immunization causes changes in pre-and post-synaptic structures
To examine whether the presence of anti-LRP4 antibodies results in NMJ structural changes, we performed whole-mount staining of soleus muscles from LRP4-immunized and control mice. For this experiment, we used the AChR probe BTx and antibodies against neurofilaments and synaptophysin, which label motor axons and the membranes of synaptic vesicles at nerve terminals, respectively. Confocal images were recorded and used for quantitative structural analyses. In accordance with a previous report (Shen et al., 2013) , we observed that postsynaptic structures in LRP4-immunized mice with manifestations of myasthenia had significant decreases in the staining intensity and area of AChR clusters, with BTx fluorescence staining to 30.0% and 52.0% of control levels, respectively (Figs. 4A-C) .
Recent in-vivo studies showed that LRP4 mediates presynaptic differentiation processes, such as the clustering of synaptic vesicle proteins, by acting as a muscle-derived retrograde signal (Wu et al., 2012; Yumoto et al., 2012) . Therefore, we carried out experiments to identify changes in NMJ presynaptic structures, based on the localization of bassoon. This protein concentrates at sites of synaptic vesicle fusion in nerve terminals, called active zones. Results of immunostaining studies using anti-bassoon antibodies generated in our lab showed that bassoon exhibited a small punctate staining pattern within NMJs in longitudinal sections of soleus muscles. Analysis of the confocal Z-stacks in three-dimensional reconstructions showed that the bassoon puncta were attached to the BTx signal on the nerve side in YZ-view, indicating that bassoon puncta localized within the presynaptic terminal. These features are consistent with features described in previous studies using a commercially available monoclonal Ab (Chen et al., 
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In parallel with disassembly of the NMJ postsynaptic structures, staining areas of synaptophysin and bassoon at NMJs in LRP4-immunized mice were significantly decreased to 62.6% and 55.5% of control levels, respectively (Figs. 4E-G) . However, when the bassoon-staining area was normalized to the synapse size (estimated by the synaptophysin-staining area), this area was unchanged compared to control mice. In other words, the areas of the active zone (stained with anti-bassoon Abs) were proportionally reduced with the areas of synapse vesicles (stained with anti-synaptophysin Abs) (Fig. 4H) . Taken together, these results show that the overall NMJ structure was reduced in LRP4-immunized mice, indicating that LRP4 is required for preservation of pre-and post-synaptic structures in NMJs.
Anti-LRP4 Abs inhibit agrin-induced and agrin-independent AChR clustering in vitro
LRP4 serves as the receptor for agrin and is required for agrin-induced activation of MuSK and AChR clustering (Kim et al., 2008; Zhang et al., 2008) . A previous report demonstrated that anti-LRP4 Abs interfered with this process in an in-vitro muscle cell model (Shen et al., 2013) . We asked whether, in our model, anti-LRP4 Abs would inhibit agrin-induced activation of MuSK and AChR clustering using the same methods in vitro. When C2C12 myotubes were treated with control mouse sera in the presence of agrin, numerous AChR clusters were observed. In contrast, significantly fewer clusters were observed after treatment with sera from LRP4-immunized mice in the presence of agrin (Fig. 5A) . Next, we examined the effect of anti-LRP4 Abs on the activation of MuSK, which is regulated by autophosphorylation
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19 of tyrosine residues. Sera from LRP4-immunized mice had no effect on MuSK phosphorylation in the absence of agrin but significantly inhibited agrin-induced MuSK phosphorylation (Fig.   5B ). These results demonstrate that anti-LRP4 Abs inhibited agrin-induced AChR clustering by inactivating MuSK, as was observed in a previous report (Shen et al., 2013) .
In vivo, AChR clusters exist on postsynaptic membranes at NMJs before the emergence of autoantibodies. We examined the effects of anti-LRP4 Abs on pre-existing AChR clusters induced by agrin. Treatment with sera from LRP4-immunized mice significantly decreased the number of AChR clusters within 7 h, indicating that anti-LRP4 Abs impair the maintenance of AChR clusters in vitro (Fig. 5C) . Sera from LRP4-immunized mice reduced the small number of AChR clusters that formed spontaneously in the absence of agrin, suggesting that anti-LRP4 Abs interfered with agrin-independent AChR clustering (Fig. 5A) .
In a previous study, anti-MuSK Abs from MuSK-MG patients dispersed agrin-independent Dok-7-induced AChR clusters in C2C12 myotubes (Koneczny et al., 2013) . Dok-7 is an essential intracellular MuSK-binding protein (Okada et al., 2006 ) that directly stimulates MuSK activation, bypassing the need for interaction between agrin and LRP4. We overexpressed Dok-7 in C2C12 cells by retroviral infection to determine whether anti-LRP4 Abs, similarly to anti-MuSK Abs, interfere with Dok-7-induced AChR clustering. Overexpression of Dok-7 in C2C12 myotubes promoted AChR clustering in the absence of agrin. When sera from LRP4-immunized mice were added to these myotubes, the numbers of AChR clusters were significantly reduced (Fig. 5D) . These results indicate that anti-LRP4 Abs have the capacity to impair the maintenance of agrin-independent, Dok-7-dependent AChR clusters.
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Discussion
In this study, we demonstrated that anti-LRP4 Abs, generated via active immunization with the ectodomain of human LRP4 protein, cause a comparable myasthenic weakness to the pathohistological and electrophysiological features observed in MuSK-EAMG mice (Mori et al., 2012b) . The LRP4-EAMG model was first described in 2013 (Shen et al., 2013) , when a clinically mild form of EAMG was induced in mice by active immunization with LRP4 protein isolated from whole-cell extracts of transfected HEK293 cells. Approximately one third of the actively immunized mice exhibited no weakness, even after four injections of LRP4 antigen with adjuvant over the course of 8 weeks. In our study, EAMG mice exhibited pronounced symptoms after only two or three injections of LRP4 antigen with adjuvant into A/J mice.
Although we did not directly score muscle weakness, EMG provides an objective and quantitative measurement of muscle weakness. The demonstration of a CMAP decrement in response to repetitive nerve stimulation is crucial in the diagnosis of MG in humans and EAMG in animals (Phillips et al., 2014; Plomp et al., 2015; Wu et al., 2011) . Generally, a decrement of more than 10% in the amplitude or area of the CMAP during a train of 3-Hz nerve impulses is taken as evidence of impairment of neuromuscular transmission (Phillips et al., 2014; Plomp et al., 2015; Wu et al., 2011) . Stimulation trains at higher frequencies may complicate the interpretation of this CMAP decrement, by initiating complex autoregulation of presynaptic neurotransmitter release (Noronha-Matos et al., 2011) . We found that repetitive 3-Hz stimulation induced a decrement in CMAP amplitude of more than 10% in LRP4-immunized mice. This
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An important question concerns why our recombinant LRP4 protein was able to cause MG-like myasthenia in mice. LRP4 protein could be stably purified from the culture supernatant of 293 cells transfected with expression vectors carrying the chaperone proteins MESD and RAP.
MESD binds to the less-glycosylated, intracellular form of LRP4 and facilitates its maturation into the cell-surface form by promoting its glycosylation (Hoshi et al., 2013) . N-linked glycosylation is crucial for the appropriate folding and subsequent transport of receptor proteins to the cell surface (Bonnemaison et al., 2013; Moremen et al., 2012) . Therefore, the secreted form of recombinant LRP4 protein, which is correctly folded and modified like the native form, may have an increased pathogenic potential for producing the MG-inducing Abs. In addition to MG, anti-LRP4 Abs have been found in patients with other neurological diseases. However, previous studies detected and measured the anti-LRP4 Ab titer using recombinant LRP4 protein or LRP4-expressing cell-based assays without coexpression of the chaperones RAP and MESD.
The exploration of anti-LRP4 Ab pathogenicity in patients may require the standardization of LRP4 antigens for the detection of autoantibodies.
Another question regards whether autoantibodies against LRP4 are actually pathogenic in MG patients. The detection of LRP4 Abs in other diseases adds doubt over the pathogenic role in MG (Binks et al., 2016; Evoli and Iorio, 2015) . MG-like myasthenia has not been demonstrated in animals by passive transfer of antigen-specific Abs from LRP4-MG patients; thus, it is uncertain whether human autoantibodies from LRP4-MG patients act similarly to the Abs in LRP4-immunized mice. Sera and purified IgG fractions from LRP4-MG patients disrupted interactions between agrin and the extracellular region of LRP4 and inhibited agrin-induced AChR clustering in vitro (Higuchi et al., 2011; Pevzner et al., 2012; Zhang et al., 2012) . However, the possibility remains that other unidentified pathogenic autoantibodies exist in the sera of LRP4-MG patients.
A few studies describing LRP4-MG found that the clinical presentation in seronegative patients was predominantly of a mild form with rare pathological electrophysiological test results (Nikolic et al., 2016) . The EMG recording of a CMAP decrement following repetitive low-frequency stimulation is crucial in the diagnosis of MG in patients and animal models (Phillips et al., 2014; Plomp et al., 2015) . Furthermore, ex-vivo endplate recordings can reveal the precise synaptic impairment at NMJs (Plomp et al., 2015) . We detected the typical CMAP of less than 10 Hz in LRP4-MG mice, indicating that there was MG-like neurotransmission failure in the NMJs. In addition, our and others' LRP4-MG mice demonstrated reduced MEPP amplitude and quantal content, suggesting diminished postsynaptic sensitivity and defective release of presynaptic neurotransmitters, respectively, as has been observed in MuSK-MG patients and mice (Mori et al., 2012b; Plomp et al., 2015; Shen et al., 2013) . In cases of AChR-MG patients and models, compensatory upregulation of presynaptic ACh release can be monitored as an increase of quantal content with reduced MEPP amplitude, implicating
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Histopathological data of NMJs in LRP4-MG patients are not yet available for comparison with other MG patients and models. LRP4-immunized, complement-deficient mice exhibited pronounced MG-like symptoms at a high incidence, showing that complement activation is dispensable for onset of LRP4-EAMG in mice. On the other hand, most of the anti-LRP4 Abs that have been detected in patients have belonged to IgG1-3 subclasses, which are able to activate complement (Higuchi et al., 2011; . Our LRP4-EAMG mice also exhibited production of complement-fixing IgG2a and IgG2b subclasses, although the presence of these Abs might reflect the shift of immune response toward the Th1 phenotype, which Freund's adjuvant is known to induce (Ulusoy et al., 2014) . Therefore, at present, we cannot completely exclude that possibility that complement activation is involved in the onset of LRP4-MG in complement-sufficient animals, including humans. However, we previously demonstrated that the production of complement-fixing Abs was not necessarily connected to damage to postsynaptic membranes in a complement-sufficient rabbit model of MuSK-EAMG (Mori et al., 2012c) . Thus, the importance of complement in LRP4-MG should be further investigated by EAMG experiments, such as by using exogenous supplementation of complement components. If complement-mediated damage to NMJs is involved in the onset of LRP4-MG, as has been observed in AChR-MG, complement deposition or morphological destruction with AChR loss at the postsynaptic membrane of NMJs could be observed.
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Alternatively, the reduction of the presynaptic area of NMJs in LRP4-MG patients, as has been observed in LRP4-MG mice, strongly suggests the involvement of LRP4 in MG pathogenicity. Intriguingly, double-positive patients (AChR/LRP4 Abs or MuSK/LRP4 Abs) tend to have more severe symptoms (Evoli and Iorio, 2015) . It might be interesting to examine the precise ex-vivo electrophysiology using sera and the histology using muscle biopsies from AChR-MG and MuSK-MG patients, as has been performed previously (Burges et al., 1994; Engel et al., 1977; Klooster et al., 2012; Niks et al., 2010; Viegas et al., 2012) .
Besides serving as a tool for MG studies, LRP4-MG mice can aid in elucidating the roles of LRP4 in maintaining the structural and functional integrity of NMJs. Using LRP4-MG models, we and others have demonstrated that LPR4 plays crucial roles in NMJs, by acting bi-directionally between pre-and post-synapses (Shen et al., 2013) . In this study, we unexpectedly found that agrin-independent AChR clustering by Dok-7 was inhibited by anti-LRP4 Abs, similarly to anti-MuSK Abs, in cultured myotubes (and, probably, in NMJs as well) (Koneczny et al., 2013) . In vivo, LRP4 has been shown to form a complex with MuSK to promote muscle prepatterning, which involves formation of small AChR clusters before innervation in a specific muscle region where synaptic contacts will be established independent of agrin binding to LRP4 (Kim et al., 2008; Weatherbee et al., 2006; Zhang et al., 2008) .
Furthermore, a recent study demonstrated that LRP4 is required for efficient activation of MuSK by Dok-7 in muscle. Findings from that study further suggested that the interaction between LRP4 and MuSK induces conformational changes in MuSK that promote its susceptibility to Dok-7-mediated activation (Tezuka et al., 2014) . Taken together, our results demonstrate that
anti-LRP4 Abs also disrupt the LRP4-MuSK interaction, which inhibits LRP4 function. Recently, conditionally mutant mice in which LRP4 was deleted specifically in adult muscles were shown to exhibit structural and functional defects associated with pre-and post-synaptic components, which resulted in myasthenic symptoms (Barik et al., 2014) . Further studies are required to understand the roles of LRP4 in the maintenance of NMJs. 
